Advanced bladder cancer in 2021: Going forward?
Live from the studio: Plenary Session 03

Saturday 10 July
11:00 - 12:30

Location
Virtual room 1

Chairs
M. De Santis, Berlin (DE)
J. Palou, Barcelona (ES)
M. Rouprêt, Paris (FR)
A. Stenzl, Tübingen (DE)

Learning objectives
Scientific efforts of the last decade have yielded several novel diagnostic and therapeutic opportunities for patients suffering from MIBC and metastatic disease. The learning objectives of this session are:

- Go through technical innovations such as next-generation sequencing which have enabled the comprehensive molecular classification of MIBC.
- Improve personalized and targeted therapeutical strategies by administration of highly selective drugs with good tolerability, in neoadjuvant and adjuvant settings.
- Describe technological advances in imaging and in surgery may which improve risk stratification and eventually improve the outcomes of bladder cancer patients.

11:00 - 11:10
State-of-the-art lecture Safe and optimal management of MIBC in the time of SARS-COV-2
J.W.F. Catto, Sheffield (GB)

11:10 - 11:20
Confederación Americana de Urología (CAU) lecture What is the role of TUR in MIBC?
A.R. Rodriguez, Rochester (US)

11:20 - 11:37
Debate

11:20 - 11:25
Pro: Robotic radical cystectomy and neobladder - concrete advantages of the robotic approach
A. Gallina, Milan (IT)

11:25 - 11:30
Con: Open radical cystectomy and neobladder - still the gold standard surgery
O. Rodriguez Faba, Barcelona (ES)

11:30 - 11:37
Discussion

11:37 - 11:42
Is there a role for neoadjuvant immunotherapy in MIBC?
To be confirmed

11:42 - 11:47
The role of imaging in the neoadjuvant setting CT, PET/CT or MRI?
A. Messina, Milan (IT)

11:47 - 12:10
Clinical complete response after neoadjuvant chemotherapy for MIBC: Do we always need to perform a cystectomy?

11:47 - 11:52
Clinical case presentation
A. Masson-Lecomte, Paris (FR)

11:52 - 11:57
Oncologist’s point of view
M. De Santis, Berlin (DE)

11:57 - 12:02
Urologist’s point of view
M.J. Ribal Caparros, Barcelona (ES)

12:02 - 12:10
Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Type</th>
<th>Title</th>
<th>Speaker and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10 - 12:20</td>
<td>State-of-the-art lecture</td>
<td>Molecular markers in MIBC: Can we use them to decide treatment?</td>
<td>L. Dyrskjøt, Aarhus (DK)</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>State-of-the-art lecture</td>
<td>Does every metastatic patient need immunotherapy in a first-line setting?</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>